Search the Newsreel

What Does Gilead Sciences (GILD) Gain From Its Expanded EU Breast Cancer Approval?

Gilead Sciences (NasdaqGS:GILD) received expanded European Commission approval for Trodelvy in combination with Keytruda as a first-line treatment for metastatic triple-negative breast cancer across PD-L1 status in Europe. The decision establishes Trodelvy plus Keytruda as the first antibody-drug conjugate and immunotherapy combination approved for …

Gilead Sciences to Present at Upcoming Third Quarter 2026 Investor Conferences

FOSTER CITY, Calif., August 26, 2026--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: Wells Fargo Annual Healthcare Conference on Wednesday, September 9 at 11:00 AM Eastern Time Cantor Global Healthcare Conference on Thursday, …

Gilead Sciences Has Snapped Out of Its Slump -- and 1 Catalyst Is Doing Most of the Heavy Lifting

After months of sideways price action, Gilead Sciences (NASDAQ: GILD) has started zooming higher. This comes on the heels of the pharmaceutical company's latest quarterly earnings release. Trading around $130 per share ahead of earnings, the stock has since surged to around $146 per …

European Commission Expands Role of Gilead’s Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer Across PD-L1 Status

– European Approval Received for Trodelvy plus Pembrolizumab in First-Line PD-L1-Positive Metastatic Triple-Negative Breast Cancer (TNBC) – – Approval Establishes Trodelvy as the First and Only Antibody-Drug Conjugate for the Treatment of First-Line Metastatic TNBC, Across PD-L1 Status – FOSTER CITY, Calif., August 24, …

Gilead’s Core Business Is Accelerating, But Will Its $11 Billion Pipeline Bet Pay Off?

Gilead Sciences, Inc. (NASDAQ:GILD) produced an unusual earnings report in fiscal Q2 2026. Its commercial portfolio delivered double-digit growth, and yet the company posted one of the largest quarterly losses in its recent history. So where did the disconnect come from? It was created …

Gilead’s HIV Business is Surging, but is the Company Too Dependent on One Franchise?

Gilead Sciences, Inc. (NASDAQ:GILD) delivered strong fiscal Q2 2026 results, with total revenue rising 10% year over year to approximately $7.8 billion. The performance was primarily driven by continued growth across its HIV franchise, including Biktarvy and the newly launched Yeztugo. Gilead also raised …

Gilead’s Revenue Is Accelerating, But are its Acquisitions Worth the Cost?

Gilead Sciences, Inc. (NASDAQ:GILD) delivered its strongest commercial momentum in several years during fiscal Q2 2026, with growth extending across HIV, oncology, and liver disease. Total revenue increased 10% year over year to approximately $7.8 billion, while product sales rose 8% to $7.6 billion. …

Does Gilead (GILD) Pairing With Nucleai Reveal a Deeper Shift in Its Oncology Strategy?

In August 2026, Nucleai announced an ongoing translational research collaboration with Gilead Sciences, using AI-powered tissue analytics to support Gilead's global antibody-drug conjugate clinical development programs across multiple oncology indications. The partnership highlights how integrating AI-native computational pathology with clinical outcomes may help standardize …

El director financiero de Gilead Sciences vende acciones por 415.000 dólares

Is Gilead's Expanding HIV Portfolio a Growth Catalyst?

Gilead Sciences, Inc. GILD has a market-leading HIV franchise, led by flagship HIV therapies — Biktarvy for treatment and Descovy for prevention. Earlier this month, the company reported better-than-expected second-quarter results, driven by strong HIV breast cancer drug Trodelvy and liver disease drug Livdelzi …

Gilead Sciences Has Quietly Become One of the Most Underrated Turnaround Stories in Healthcare. Here's Why Wall Street Is Excited.

Gilead Sciences (NASDAQ: GILD) has shifted from a period of stagnant growth, driven by slowing hepatitis C revenues and declining sales of its COVID-19 therapy Veklury, to a turnaround led by new HIV and oncology drugs. The pharmaceutical stock is up more than 12% …

Gilead Sciences (GILD): Buy, Sell, or Hold Post Q2 Earnings?

Gilead Sciences (GILD): Buy, Sell, or Hold Post Q2 Earnings? Over the last six months, Gilead Sciences's shares have sunk to $137.77, producing a disappointing 11.3% loss - a stark contrast to the S&P 500's 13.1% gain. This might have investors contemplating their next …

Can MacroGenics (MGNX) Turn Gilead Sciences (GILD)’s $10M Milestone Into a Major Pipeline Catalyst?

On August 11, Gilead Sciences, Inc. (NASDAQ:GILD) exercised its option to exclusively license a preclinical bispecific program targeting solid tumors using MacroGenics, Inc. (NASDAQ:MGNX)'s proprietary TRIDENT platform. The decision triggered a $10 million milestone payment to MacroGenics, injecting momentum into the companies' 2022 collaboration. …

Could Merck & Co., Inc. (MRK) and Gilead Sciences, Inc. (GILD)’s Partnership Create the Next Big Pharma Growth Engine

Two biopharma giants, Merck & Co., Inc. (NYSE:MRK) and Gilead Sciences, Inc. (NASDAQ:GILD), are proving that in modern drug development, the biggest catalyst isn't always competing head-to-head; it is knowing when to join forces. While both companies reported their first-quarter 2026 earnings earlier this …

Gilead (GILD) Stock Still Looks Cheap On Sales Despite A 127% Run

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Gilead Sciences stock has delivered a 126.6% total return over the past 5 years, and the current valuation checks still lean on the …

Why Gilead Sciences (GILD) Is Back In The Spotlight

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Gilead Sciences (GILD) is back in focus after announcing a collaboration with Nucleai that applies AI powered tissue analytics to its antibody drug conjugate …

Gilead Sciences (GILD) Expands ADC Research With AI Tissue Analytics

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Gilead Sciences (NasdaqGS:GILD) announced a partnership with Nucleai to use AI-powered tissue analytics in its global antibody drug conjugate programs. The collaboration focuses …

TNGX Stock Dips 5% as Q2 Earnings Miss Estimates on Higher Expenses

Tango Therapeutics TNGX incurred a loss of 37 cents per share in the second quarter of 2026, wider than the Zacks Consensus Estimate of a loss of 31 cents. The company had reported a loss of 35 cents per share in the year-ago quarter. …

3 Healthcare Stocks with Open Questions

3 Healthcare Stocks with Open Questions Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 22.3% gain over …

MacroGenics Announces Achievement of $10 Million Milestone Following Gilead’s Exercise of Option to License Preclinical Bispecific Program

MacroGenics, Inc. ROCKVILLE, MD, Aug. 11, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that Gilead Sciences, Inc. has exercised its option to obtain an exclusive license …

J&J Trading Above 200- & 50-Day SMAs: Buy, Sell or Hold the Stock?

Johnson & Johnson JNJ stock has been trading above both its 50-day and 200-day simple moving averages (SMAs) since mid-June. Trading above the 200-day SMA indicates that the stock's longer-term trend has turned positive, while staying above the 50-day SMA suggests that shorter-term momentum …

Nucleai Advances AI-Powered Tissue Intelligence Through Large-Scale Oncology ADC Collaboration

Collaboration demonstrates how AI-powered Tissue Intelligence is transforming biomarker discovery, translational research, and precision oncology development. TEL AVIV, Israel, August 11, 2026--(BUSINESS WIRE)--Nucleai, a leader in AI-powered Tissue Intelligence, which integrates multimodal tissue image analysis with clinical data to deliver translational insights, today announced …

The Galien Foundation Announces 2026 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Product," and "Best Product for Rare/Orphan Diseases"

A Milestone 20th Anniversary Edition Recognizing Excellence in Medical Science and Patient Care NEW YORK, Aug. 11, 2026 /PRNewswire/ -- The Galien Foundation, the premier global institution dedicated to honoring innovators in life sciences, today announced the nominees for the 2026 Prix Galien USA …

Non-Viral Transfection Reagents Market Report (3rd Edition) by Type of Non-Viral Transfection Method, Application Area, End-User & Region, Featuring Bio-Rad, MaxCyte, MilliporeSigma, Thermo Fisher Scientific

Company Logo Dublin, Aug. 11, 2026 (GLOBE NEWSWIRE) -- The "Non-Viral Transfection Reagents Market (3rd Edition) by Type of Non-Viral Transfection Method, Application Area, End-User and Geographical Regions-Trends and Forecast Till 2035" has been added to ResearchAndMarkets.com's offering. The global non-viral transfection reagents market …

Lakefront Biotherapeutics Reports Half-Year 2026 Financial Results and Provides Business Update

Lakefront Biotherapeutics Completed acquisition of Ouro Medicines with Gilead Sciences to advance potential first and best-in-class T-cell engager Forecast at least €1.6B of cash remaining after funding portfolio to first gamgertamig approval Maintain year-end 2026 cash and financial investments balance guidance of ~€2B, and …

GILD- An Attractive Biotech Stock with Solid Base Revenue Growth

Gilead Sciences Inc. (GILD) just reported June quarter revenue up 10.2% from last year to $7.8 billion, ahead of estimates. Due to an $11.2 billion one-time write-off of acquired in-process R&D, they reported a $6.75 per share pro forma loss. But that was smaller …

Key HIV stat over 70% leaves BofA siding with Gilead

Gilead Sciences (GILD) closed a strong second quarter, and Wall Street noticed. The drugmaker beat sales expectations across its biggest franchises, raised its full-year outlook, and gave analysts fresh reasons to stay bullish heading into the back half of 2026. Bank of America was …

Noticias de acciones de Gilead Sciences Inc (GILD)

GILD Q2 Earnings Call Raises Outlook on HIV and PrEP Strength

Gilead Sciences, Inc. GILD used its second-quarter 2026 call to emphasize stronger base-business growth, led by HIV, PrEP, Trodelvy and Livdelzi, while outlining a busy second-half launch calendar. Non-GAAP loss per share was $6.75, better than the Zacks Consensus Estimate for a loss of …

KYMR Q2 Earnings and Revenues Top Estimates on Gilead, Sanofi Payments

Kymera Therapeutics, Inc. KYMR reported a second-quarter 2026 loss of 62 cents per share, narrower than the Zacks Consensus Estimate of a loss of 64 cents. The company posted a loss of 95 cents in the year-ago period. Revenues surged to $65 million from …

Gilead Slumps As Long-Term Uncertainty Clouds Massive HIV Beat

Gilead Sciences narrowly beat sales expectations for its HIV PrEP drug, Yeztugo. Gilead stock slipped, still in a downtrend. Continue Reading

Gilead (GILD) Faces HIV Drug Access Criticism From AIDS Healthcare Foundation

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. AIDS Healthcare Foundation publicly criticizes Gilead Sciences on its global HIV drug pricing and access policies. The advocacy group alleges that Gilead benefits from taxpayer-funded research while …

The Bull Case For Gilead Sciences (GILD) Could Change Following Deeper 2026 Losses Amid HIV, Oncology Growth

In early August 2026, Gilead Sciences reported second-quarter revenue of US$7.80 billion but moved to a quarterly net loss of US$10.50 billion, widened its full-year 2026 loss guidance, and still affirmed a US$0.82 per-share dividend while continuing selective share repurchases. Despite the reported loss …